Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan

AstraZeneca's (AZN) PARP inhibitor, Lynparza, receives approval for treating ovarian cancer in Japan, following its label expansion in the United States.

AZN : 35.90 (+1.30%)
MRK : 61.12 (-0.26%)
CLVS : 60.88 (+7.26%)
TSRO : 68.72 (+7.53%)
Foreign Stock Roundup: Taiwan Semiconductor Beats, Shell Buys Stake in Silicon Ranch

Global markets largely echoed Wall Street's fortunes over last week.

PBR : 12.18 (+0.16%)
AZN : 35.90 (+1.30%)
MRK : 61.12 (-0.26%)
ERIC : 7.20 (-1.23%)
RDS.A : 70.83 (+1.43%)
TM : 139.19 (-0.47%)
TEVA : 20.97 (+1.30%)
ATLKY : 47.4300 (-0.19%)
TSM : 46.26 (+3.56%)
Cancer Space Update: Label Expansions, Data Readouts in Focus

This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.

AZN : 35.90 (+1.30%)
MRK : 61.12 (-0.26%)
AGN : 187.35 (+3.32%)
NVS : 86.76 (-0.21%)
EXEL : 29.43 (+5.11%)
RHHBY : 30.7000 (+0.03%)
AMGN : 192.10 (+1.49%)
BLRX : 1.05 (-3.67%)
Here's Why Nektar Stock Skyrocketed Almost 500% in a Year

Nektar's (NKTR) shares soar in a year's time on a robust pipeline including several study initiations, positive readouts and strategic collaborations.

AZN : 35.90 (+1.30%)
MRK : 61.12 (-0.26%)
AMGN : 192.10 (+1.49%)
NKTR : 76.53 (+6.90%)
Nektar Boasts Strong Pipeline, Competition Remains a Woe

Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.

AZN : 35.90 (+1.30%)
LLY : 85.12 (-0.43%)
SHPG : 147.53 (+1.75%)
NKTR : 76.53 (+6.90%)
AstraZeneca's Lynparza Label Now Includes Breast Cancer

AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.

AZN : 35.90 (+1.30%)
MRK : 61.12 (-0.26%)
MYGN : 39.64 (+2.64%)
CLVS : 60.88 (+7.26%)
Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU

Global markets endured a volatile week, guided by opposing factors.

AZN : 35.90 (+1.30%)
NVO : 57.82 (+0.05%)
MT : 36.90 (+0.08%)
ITUB : 15.03 (+1.69%)
INFY : 18.02 (+0.17%)
VALE : 13.24 (-0.90%)
PHG : 40.83 (-0.49%)
HMC : 36.12 (-0.33%)
US OKs 1st drug aimed at women with inherited breast cancer

U.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.

AZN.LS : 5,043.000 (+1.52%)
AZN : 35.90 (+1.30%)
LYNPARZA(R) (olaparib) Approved by US FDA in Germline BRCA-Mutated Metastatic Breast Cancer

--LYNPARZA reduced the risk of disease progression or death by 42% compared to standard of care chemotherapy

AZN : 35.90 (+1.30%)
MRK : 61.12 (-0.26%)
MYGN : 39.64 (+2.64%)
AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU

AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.

AZN : 35.90 (+1.30%)
TEVA : 20.97 (+1.30%)
AMGN : 192.10 (+1.49%)
GSK : 38.43 (+0.60%)
Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes

Novo Nordisk (NVO) announced that Health Canada has approved Ozempic to improve glycemic control in adults with type II diabetes mellitus.

AZN : 35.90 (+1.30%)
NVO : 57.82 (+0.05%)
MRK : 61.12 (-0.26%)
SNY : 43.11 (-3.34%)
Pharma Stock Roundup: Allergan Announces Job Cuts, Pfizer Inks Deals

In a relatively slow week, Allergan's (AGN) job cut announcement remained the key highlight while Pfizer's collaboration agreements with Sangamo and Arvinas were also in focus.

MYL : 47.44 (+1.52%)
AZN : 35.90 (+1.30%)
AGN : 187.35 (+3.32%)
RHHBY : 30.7000 (+0.03%)
PFE : 36.78 (-0.43%)
GSK : 38.43 (+0.60%)
Wired News - Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca

Stock Monitor: AstraZeneca Post Earnings Reporting

AZN : 35.90 (+1.30%)
MYGN : 39.64 (+2.64%)
The Zacks Analyst Blog Highlights: Apple, Mastercard, 3M, AstraZeneca and Mondelez

The Zacks Analyst Blog Highlights: Apple, Mastercard, 3M, AstraZeneca and Mondelez

MDLZ : 44.18 (+0.09%)
AAPL : 177.00 (-0.82%)
MA : 167.35 (+0.31%)
AZN : 35.90 (+1.30%)
MMM : 246.85 (-0.54%)
Top Analyst Reports for Apple, Mastercard & 3M

Top Analyst Reports for Apple, Mastercard & 3M

MDLZ : 44.18 (+0.09%)
AAPL : 177.00 (-0.82%)
MA : 167.35 (+0.31%)
AZN : 35.90 (+1.30%)
MMM : 246.85 (-0.54%)
CB : 149.31 (+0.75%)
Can Merck Regain its Mojo in 2018 After an Unimpressive '17?

Merck's (MRK) shares declined in 2017 against an increase witnessed by the large-cap pharma industry. It remains to be seen if the company regains momentum in 2018.

AZN : 35.90 (+1.30%)
NVO : 57.82 (+0.05%)
JNJ : 147.36 (-0.05%)
MRK : 61.12 (-0.26%)
The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S

The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S

AZN : 35.90 (+1.30%)
NVO : 57.82 (+0.05%)
JNJ : 147.36 (-0.05%)
ABBV : 105.94 (+1.24%)
RHHBY : 30.7000 (+0.03%)
4 Large-Cap Pharma Stocks That Outperformed the S&P This Year

We take a look at a few Large Cap stocks, which have surpassed the S&P 500 index in 2017 due to upsides on both regulatory and pipeline fronts.

AZN : 35.90 (+1.30%)
NVO : 57.82 (+0.05%)
JNJ : 147.36 (-0.05%)
ABBV : 105.94 (+1.24%)
RHHBY : 30.7000 (+0.03%)
What Drives Juno Therapeutics (JUNO) Above 150% This Year

We take a look at the factors especially the focus on CAR-T therapy that led to the phenomenal growth in Juno Therapeutics (JUNO) share price in 2017.

CELG : 102.96 (+0.30%)
AZN : 35.90 (+1.30%)
SCMP : 17.92 (-0.17%)
JUNO : 85.92 (+26.71%)
Pharma Stock Roundup: Roche, MNK Announce Acquisition Agreements, Regulatory Updates from Novartis

Although it's been a relatively slow week, two acquisition deals were announced with Roche (RHHBY) saying it will acquire Ignyta while Mallinckrodt will buy Sucampo.

AZN : 35.90 (+1.30%)
AGN : 187.35 (+3.32%)
NVS : 86.76 (-0.21%)
MNK : 21.86 (+2.63%)
RHHBY : 30.7000 (+0.03%)
GSK : 38.43 (+0.60%)
BMY : 62.83 (+0.88%)

Van Meerten Stock Picks

My 5 Favorite Mid Cap Stocks
This morning I wanted to find 5 Mid Cap stocks that had great returns over the past year and still seem to have some juice left.
KBH -0.03 , IPGP -1.25 , FSLR -1.11 , NVR -54.02 , SGMS -0.48
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 -0.06% ) this morning are down -0.07% as the partial shutdown of the U.S. government begins for a third day. The Senate has a vote scheduled for 12pm Eastern time to sees if the impasse... Read More

Chart of the Day

Chart of the Day

Catalyst Biosciences (CBIO) is the Barchart Chart of the Day.  The biomedical company has a Trend Spotter buy signal, a Weighted Alpha of 150.22+ and gined 111.86% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures are showing fractional gains at midday. This morning's USDA Export Inspections report, not affected by the government shutdown, showed shipments of 668,948 MT for the week that ended 1/18. That was 13.62% above the previous week but stil...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.